Welcome, Guest. Please login or register.
August 06, 2020, 03:40:06 pm

Login with username, password and session length


Members
  • Total Members: 35450
  • Latest: M2584
Stats
  • Total Posts: 755514
  • Total Topics: 63823
  • Online Today: 366
  • Online Ever: 4912
  • (November 13, 2019, 02:56:14 am)
Users Online
Users: 2
Guests: 286
Total: 288

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: integrase inhibitors - risk of diabetes?  (Read 1087 times)

0 Members and 1 Guest are viewing this topic.

Online Jim Allen

  • Administrator
  • Member
  • Posts: 15,798
  • Twitter @JimAllenDublin
    • HIV Lessons
integrase inhibitors - risk of diabetes?
« on: October 24, 2019, 02:40:34 pm »
To be honest, I read both the POZ report, Aids map report and the study.

My personal take away was it's far from conclusive but hard to ignore, that said no need to panic just more reason to manage my diet better and reduce risks from factors I can directly control.

Jim

POZ.com write-up: https://www.poz.com/article/integrase-inhibitors-may-raise-diabetes-risk-people-hiv

In short;

Quote
Integrase inhibitors, a newer class of antiretrovirals (ARVs), may be associated with an increased risk of diabetes, although this finding may vary based on the specific medication, aidsmap reports.

Presenting his research teamís findings at the IDWeek meeting in Washington, DC, earlier this month, Peter Rebeiro, PhD, of Vanderbilt University Medical Center in Tennessee, analyzed the association between different classes of ARVs and a diabetes diagnosis among 21,516 people with HIV in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) cohort.

The participants were all starting ARVs for the first time between 2007 and 2016 with regimens that included a non-nucleoside reverse transcriptase inhibitor, or NNRTI (10,553 people, or 49% of the cohort), protease inhibitor (6,677, or 31%) or integrase inhibitor (4,286, or 20%).

Among those who started an integrase inhibitor, 51% took elvitegravir (marketed as the stand-alone drug Vitekta and included in the Stribild and Genvoya combination pills), 28% took raltegravir (Isentress) and 21% took dolutegravir (Tivicay, also in the Triumeq, Juluca and Dovato combo pills).

Eighty-seven percent of the participants were men, and about 40% were white. Among those taking NNRTIs, protease inhibitors and integrase inhibitors, the median age was 42, 41 and 38 years old, respectively; the median CD4 count was 313, 262 and 360, respectively; and the median follow-up time was 3.05, 2.35 and 1.62 years, respectively.

Three percent of the participants were diagnosed with diabetes during follow-up. The diagnosis rate per 1,000 cumulative years of follow-up was 9.2, 11.8 and 12.0 diagnoses among those taking NNRTIs, protease inhbitors and integrase inhibitors, respectively.

This meant that those who started on integrase inhibitors were 22% more likely to receive a diabetes diagnosis compared with those who started taking NNRTIs; this difference was not quite statistically significant, meaning it may have been driven by chance. However, taking integrase inhibitors was associated with a statistically significant 25% increased risk of diabetes compared with taking protease inhibitors.

In the integrase inhibitor group, the diabetes diagnosis rate per 1,000 cumulative years of follow-up was 10.7, 16.2 and 15.6 diagnoses among those who took elvitegravir, raltegravir and dolutegravir, respectively. Compared with starting on NNRTIs, doing so with raltegravir was associated with a statistically significant 50% increased risk of diabetes, while doing so with the other two integrase inhibitors was not associated with significantly increased risk of the diagnosis.

The study authors concluded that further research is needed to determine whether the apparent elevated risk of diabetes associated with integrase inhibitors is driven by weight gain.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Offline Tonny2

  • Member
  • Posts: 2,310
Re: integrase inhibitors - risk of diabetes?
« Reply #1 on: October 24, 2019, 07:29:46 pm »


        ojo.        Well, I've been taking for almost 13 years:

Prezista/norvir

Intelence

Raltegeavir

So far, no diabetes


Offline Mightysure

  • Member
  • Posts: 428
Re: integrase inhibitors - risk of diabetes?
« Reply #2 on: October 28, 2019, 02:39:24 pm »
I would like to see how they controlled for any genetic or lifestyle predisposition to diabetes because correlation is not necessarily causation from one study.

 


Terms of Membership for these forums
 

© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.